SAGE Therapeutics to Participate in the 4th Annual Leerink Partners Rare Disease Roundtable

CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) — SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer, and Kimi Iguchi, Chief Financial Officer, will participate in an analyst-led fireside chat at the 4th Annual Leerink Partners Rare Disease Roundtable from 12:30 to 12:50 p.m. ET on Wednesday, Sept. 30 in New York City.The live webcast can be accessed on the investor page of SAGE’s website at A replay of the webcast will also be archived for up to 30 days on SAGE’s website following the conference.About SAGE TherapeuticsSAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system (CNS) disorders. SAGE’s lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus (SRSE) and is the first of several compounds the Company is developing in its portfolio of potential CNS medicines. SAGE’s proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit StatementsVarious statements in this release concerning SAGE’s future expectations, plans and prospects, including without limitation, SAGE’s expectations regarding the advancement and potential commercialization of its product candidates, including SAGE-547, constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation: SAGE’s ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; obtaining and maintaining intellectual property protection and other forms of marketing and data exclusivity for SAGE’s products; SAGE’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; competition from others developing products for similar uses; SAGE’s ability to manage operating expenses; SAGE’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives; SAGE’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in SAGE’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in SAGE’s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE’s views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements.Investor Contact:
Paul Cox, SAGE Therapeutics


Media Contact:
Dan Budwick, Pure Communications